JP Morgan Chase’s Aimmune Therapeutics AIMT Stock Holding History

JP Morgan Chase’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-20,000	Closed	-$419K	–	6018
2019 Q3	$419K	Sell	20,000 -15,000	-43%	-$306K	﹤0.01%	4249
2019 Q2	$697K	Sell	35,000 -1,100	-3%	-$22.6K	﹤0.01%	4060
2019 Q1	$807K	Sell	36,100 -65,700	-65%	-$1.55M	﹤0.01%	3926
2018 Q4	$2.44M	Buy	+101,800	New	+$2.63M	﹤0.01%	3138
2018 Q2	–	Sell	-36,000	Closed	-$1.15M	–	5783
2018 Q1	$1.15M	Buy	+36,000	New	+$1.27M	﹤0.01%	3598

JP Morgan Chase's AIMT Position: Q4 2020 in Review

JP Morgan Chase sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 1,058,899 shares — an estimated $36.4M sold.

JP Morgan Chase first reported a position in AIMT in Q1 2016 and held it in 19 quarters. The position peaked at $36.4M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

JP Morgan Chase reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
JP Morgan Chase sold 1,058,899 Aimmune Therapeutics shares in Q4 2020, an estimated $36.4M.
JP Morgan Chase first reported a position in Aimmune Therapeutics in Q1 2016 and held it in 19 quarters.
JP Morgan Chase's Aimmune Therapeutics position peaked at $36.4M in Q3 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on JP Morgan Chase's 13F filing for Q4 2020, filed 11 Feb 2021.